Powered by
Acasti Pharma Forms Scientific Advisory Board and Appoints Two Leading Cardiovascular Disease Experts
Mar 8, 2017 - Marketwired
Board and Executive Moves

Acasti Pharma Inc. (NASDAQ:ACST)(TSX VENTURE:ACST) today announced the appointment of Barry A. Franklin, Ph.D. and Robert Hegele, M.D. to its newly formed Scientific Advisory Board. Drs. Franklin and Hegele will advise Acasti on scientific matters and on the clinical development of CaPre(R), the company's krill-based omega-3 phospholipid for the treatment of patients with severe hypertriglyceridemia, a metabolic condition that contributes to increased risk of cardiovascular disease and pancreati

Sign up for unrestricted access to 200+ subscription services.
Already have an account? Click here to login.

RelSci News & Alerts gets you:

  • 5 free articles a month from top subscription outlets like the Financial Times, New York Times, and Washington Post
  • Competitive business intelligence through daily data updates
  • Custom feeds on target high-value individuals, companies, industries, and topics delivered straight to your inbox